Bliss GVS Pharma Ltd. (BLISSGVS-BE) 52 Week High Streak: Second Straight Session at Rs 644

Summary: Bliss GVS Pharma Ltd. has now set a fresh 52-week high for its second straight session, with the streak up 4.48% from the start of the run to Rs 644. The latest peak matches the current price, and the supplied data confirms the pattern of repeated highs but does not establish a company-specific catalyst for the move.

As of 02 September 2026 at 10:18 AM IST, the stock last traded at Rs 644 against a previous close of Rs 629.65. It opened at Rs 639.95 and touched a low of Rs 605.35, while turnover stood at Rs 0.23 crore and market capitalisation at Rs 6,550.8 crore. Compared with a single-day breakout, this repeated-high pattern is more useful for readers because it shows follow-through across sessions rather than one isolated print.

Bliss GVS Pharma Ltd. 52 Week High Streak: Consecutive High Analysis

Metric	Value
Current Price	Rs 644
Previous Close	Rs 629.65
Today's Move	+Rs 14.35 (+2.28%)
Open	Rs 639.95
High	Rs 644
Low	Rs 605.35
Turnover	Rs 0.23 crore
Market Capitalisation	Rs 6,550.8 crore

Bliss GVS Pharma Ltd. (BLISSGVS-BE) traded at Rs 644 versus the previous close of Rs 629.65, a rise of 2.28%. The stock opened at Rs 639.95, reached a high of Rs 644 and touched a low of Rs 605.35.

Bliss GVS Pharma Ltd. share price today stayed aligned with the fresh 52-week high streak, with the stock last traded at Rs 644, up Rs 14.35 or 2.28% from the previous close of Rs 629.65. The session opened at Rs 639.95, moved between Rs 605.35 and Rs 644, and printed the day’s high at the same Rs 644 level that marks the new one-year peak. That places the latest trade at the top of the day’s range, while the low shows that the stock also saw a wider intraday swing before recovering to the peak.

The turnover of Rs 0.23 crore gives a factual trading-value reference for the session, while market capitalisation stood at Rs 6,550.8 crore. For readers tracking Bliss GVS Pharma Ltd. stock news, the key point is not just today’s move but the fact that the share price has kept revisiting fresh highs on consecutive sessions. The Day-1 breakout has now turned into a second straight session at a new peak, which makes this a streak-based market event rather than a one-day price spike.

What the Repeated 52-Week Highs Show

Bliss GVS Pharma Ltd. 52 week high streak now stands at a second straight session, and that repeated pattern is the central development to watch. The supplied data shows a cumulative gain of 4.48% across the streak, which is the clearest measure of how far the stock has moved since the first fresh high in this run. The latest 52-week high is Rs 644, and that is also the current price, so the stock is trading at the new peak rather than below it.

The important distinction is that the data confirms a pattern of consecutive 52-week highs, but it does not confirm why the pattern is continuing. For a reader searching for why is Bliss GVS Pharma Ltd. still hitting 52 week highs, the honest answer is that the supplied numbers show the repeated one-year high sequence, yet they do not establish a company-specific trigger. That makes the streak a factual market event first, with interpretation limited to the price action itself and the cumulative move across the run.

Bliss GVS Pharma Ltd. new one year high behaviour can matter for monitoring because repeated highs often change how the stock is followed in market news and stock performance screens. Even so, the data here should be read as evidence of continued price progress, not as proof of a fresh operating development or a new catalyst.

Bliss GVS Pharma Ltd. (BLISSGVS-BE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 6,550.8 crore
P/E Ratio	49.14x
P/B Ratio	5.43x
ROE	12.11%
ROCE	17.4%
EPS	Rs 12.81
Book Value Per Share	Rs 116
Dividend Yield	0.24%

Bliss GVS Pharma Ltd. (BLISSGVS-BE) fundamental metrics show P/E 49.14x, P/B 5.43x, ROE 12.11%, ROCE 17.4%. These figures provide context only and are not a buy or sell signal.

Bliss GVS Pharma Ltd. has a market capitalisation of Rs 6550.8 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 49.14x, P/B at 5.43x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.11% and ROCE of 17.4%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 12.81, book value per share of Rs 116, dividend yield of 0.24%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.13x, median ROE of 11.78%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	49.14x
Benchmark Median P/E	31.13x
Benchmark Average P/E	48.11x
Benchmark P/E Range	3.68x to 653.31x
Company P/B Ratio	5.43x
Benchmark Median P/B	2.87x
Company ROE	12.11%
Benchmark Median ROE	11.78%
Company ROCE	17.4%
Benchmark Median ROCE	13.61%
Company Market Capitalisation	Rs 6,550.8 crore
Benchmark Median Market Cap	Rs 698.8 crore

Bliss GVS Pharma Ltd. (BLISSGVS-BE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a P/E ratio of 49.14x, which is above the benchmark median of 31.13x, a difference of +57.85%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a ROE of 12.11%, which is above the benchmark median of 11.78%, a difference of +2.8%. Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a ROCE of 17.4%, which is above the benchmark median of 13.61%, a difference of +27.85%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
SENORES PHARMACEUTICALS L	SENORES	6,599.71	52.97	6.94	11.78	11.94
Supriya Lifescience Ltd.	SUPRIYA	6,457.94	32.55	5.29	20.74	27.63
Innova Captab Ltd.	INNOVACAP	6,168.56	39.01	5.37	13.75	15.04
SYMBIOTEC PHARMALAB LTD	SYMBIOTEC	7,042.15	64.08	6.13	11.22	12.41
Sanofi India Ltd.	SANOFI	7,200.64	22.4	8.78	44.5	55.46

Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a P/E ratio of 49.14x compared with the displayed peer median of 39.01x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.11% compares with a peer median of 13.75% across the companies shown in the table. ROCE stood at 17.4% versus the displayed peer median of 15.04%, providing a capital-efficiency comparison. Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a market capitalisation of Rs 6,550.8 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching Bliss GVS Pharma Ltd.

• The stock has now logged a fresh 52-week high for its second straight session.
• The cumulative move across the streak is 4.48%, which is the key differentiator from a single-day breakout.
• The latest high is Rs 644, and the current price is at that same level.
• Market capitalisation stands at Rs 6,550.8 crore, keeping Bliss GVS Pharma Ltd. in a sizeable healthcare bracket.
• Valuation remains elevated versus the industry median, which keeps fundamental analysis relevant alongside the streak.

About Bliss GVS Pharma Ltd.

Bliss GVS Pharma Ltd. is a listed healthcare company in the Pharmaceuticals & Drugs industry. The market is currently tracking the stock for its repeated one-year high pattern, but the broader company lens still comes back to its financial ratios, market capitalisation and position in the pharma universe. As a stock on the NSE and BSE, it remains part of the regular market update flow for healthcare names.

From a company news perspective, the current data supports a factual read on valuation and returns rather than a catalyst-led story. Revenue figures, profitability detail and broader operating disclosures are not supplied here, so the cleanest interpretation is to focus on the metrics that are available and on how the stock is being repriced across consecutive sessions.

Track Bliss GVS Pharma Ltd. on Univest

Follow Bliss GVS Pharma Ltd. share price update, market cap movement and fresh 52-week high action on Univest for a quick view of the stock’s ongoing performance. The stock page can help readers monitor subsequent one-year high prints, valuation context and related market news in one place.

For the latest stock news, market update and peer comparison around Bliss GVS Pharma Ltd. stock analysis, keep the watchlist active as the streak develops further.

Disclaimer: This article is for informational purposes only and is based solely on the data supplied by the workflow. It is not investment advice, a recommendation, or a solicitation to buy or sell any security.

Frequently Asked Questions

How many consecutive sessions has Bliss GVS Pharma Ltd. made a fresh 52-week high?

Ans. Bliss GVS Pharma Ltd. has set a fresh 52-week high for its second straight session. The supplied data confirms the streak length directly, so the repeated-high pattern is now more important than the first breakout alone.

What is the cumulative move across the Bliss GVS Pharma Ltd. 52 week high streak?

Ans. The cumulative streak move supplied by the workflow is 4.48%. That figure captures the full move across the consecutive-high run and is the right way to read this event, rather than focusing only on the latest daily change.

What is the latest 52-week high for Bliss GVS Pharma Ltd.?

Ans. The latest 52-week high is Rs 644. The current price is also Rs 644, so the stock is trading at the new high rather than below it. The stock moved 2.28% so far today.

Did the supplied data confirm a company-specific catalyst for the repeated highs?

Ans. No. The supplied numbers confirm the repeated 52-week high pattern, but they do not establish a company-specific catalyst for the continued move. That is the most accurate reading of the available information.

How did Bliss GVS Pharma Ltd. trade in the latest session?

Ans. The stock last traded at Rs 644 versus a previous close of Rs 629.65, after opening at Rs 639.95 and moving between Rs 605.35 and Rs 644. Turnover stood at Rs 0.23 crore, with market capitalisation at Rs 6,550.8 crore.

How does Bliss GVS Pharma Ltd. compare with its industry peers on valuation?

Ans. Its P/E of 49.14 is above the industry median of 31.13, and its P/B of 5.43 is above the industry median of 2.87. That places the stock on the richer side of the supplied pharma peer sample.

What do the return ratios say about Bliss GVS Pharma Ltd.?

Ans. ROE is 12.11% and ROCE is 17.4%. Both are above the sector medians supplied in the data, which gives the stock a healthier return profile than the typical industry midpoint.

Why are investors watching Bliss GVS Pharma Ltd. now?

Ans. Investors are watching the stock because it has printed back-to-back one-year highs, moved 4.48% across the streak and is being tracked alongside a valuation that remains above sector medians. That combination keeps the name in focus on stock news screens.

Track Bliss GVS Pharma Ltd. (BLISSGVS-BE) Share Price on Univest

Use Bliss GVS Pharma Ltd. (BLISSGVS-BE) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.